Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia

Prostate-specific antigen (PSA) screening for prostate cancer (PCa) is limited by the lack of specificity but is further complicated in the benign prostatic hyperplasia (BPH) population which also exhibit elevated PSA, representing a clear unmet need to distinguish BPH from PCa. Herein, we evaluated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Kiebish, Michael A., Tekumalla, Poornima, Ravipaty, Shobha, Dobi, Albert, Srivastava, Shiv, Wu, Wenfang, Patil, Saurabh, Friss, Tracey, Klotz, Allison, Srinivasan, Alagarsamy, Cullen, Jennifer, Rosner, Inger L., Ali, Amina, Laszlo, Sandra, Petrovic, Michele, Fleshner, Neil, Garren, Jeonifer, Miller, Greg, Mahaveer Chand, Nischal, Rodrigues, Leonardo O., Granger, Elder, Kellogg, Mark D., Luan, Shen, Diamandis, Eleftherios, Akmaev, Viatcheslav R., Sarangarajan, Rangaprasad, Bountra, Chas, Freedland, Stephen J., McLeod, David G., Narain, Niven R.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8302659/
https://ncbi.nlm.nih.gov/pubmed/34302010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-94438-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados